PSMA PET in Prostate Cancer: Steve Cho

March 16, 2017

Prostate-specific membrane antigen (PSMA) has received a resurgence of attention as a useful biomarker in the imaging evaluation of prostate cancer with PET. Philip Koo, MD, welcomes Steve Cho, MD to discuss PSMA PET in prostate cancer for the inaugural lecture for the Imaging Center of Excellence on UroToday.  Dr. Cho's discusses the number of agents that are being developed in prostate cancer and how PET imaging will redefine clinical states for prostate cancer trials.

Dr. Steve Y. Cho, M.D. is an Associate Professor (CHS) in the Nuclear Medicine Section of the Department of Radiology. He is engaged in translational molecular imaging research as Director of the Translational Imaging Research Core at the University of Wisconsin Carbone Comprehensive Cancer Center, Director of the new cGMP Radiopharmaceutical Production Facility, and Associate Director of the UW PET Center. His research interest involves translational imaging, with a focus on development of novel and existing PET radiopharmaceuticals to improve clinical management and therapy development for cancer and infection. 

Philip Koo, MD

Additional resources on PSMA PET in Prostate Cancer:
The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.

Comparison of standard and delayed imaging to improve the detection rate of [(68)Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer

PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer

Comparison of PSMA-based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer